Search results
Showing 2071 to 2085 of 2183 results for guidelines
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid) and tocilizumab (RoActemra) for treating COVID-19.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
NICE publishes first quality standard to improve care for people with rare diseases
Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG92.
This guidance has been updated and replaced by NICE guideline NG130.
This guidance has been updated and replaced by NICE guideline NG88.
Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)
This guidance has been updated and replaced by NICE guideline CG186.
Venous thromboembolism: reducing the risk for patients in hospital (CG92)
This guidance has been updated and replaced by NICE guideline NG89.
This guidance has been updated and replaced by NICE guideline CG181.
This evidence summary has been updated and replaced by NICE guideline NG97.
This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Suburethral synthetic sling insertion for stress urinary incontinence in men (IPG256)
This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional procedures programme.
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.